- Home
- GILD vs DE Comparison
GILD vs DE Comparison
Compare GILD & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- DE
- Stock Information
- Founded
- GILD 1987
- DE 1837
- Country
- GILD United States
- DE United States
- Employees
- GILD N/A
- DE N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- DE Industrial Machinery/Components
- Sector
- GILD Health Care
- DE Industrials
- Exchange
- GILD Nasdaq
- DE Nasdaq
- Market Cap
- GILD 131.5B
- DE 126.4B
- IPO Year
- GILD 1992
- DE N/A
- Fundamental
- Price
- GILD $104.54
- DE $452.07
- Analyst Decision
- GILD Buy
- DE Buy
- Analyst Count
- GILD 27
- DE 17
- Target Price
- GILD $105.32
- DE $459.29
- AVG Volume (30 Days)
- GILD 10.4M
- DE 1.6M
- Earning Date
- GILD 04-24-2025
- DE 05-15-2025
- Dividend Yield
- GILD 3.02%
- DE 1.43%
- EPS Growth
- GILD N/A
- DE N/A
- EPS
- GILD 0.38
- DE 22.61
- Revenue
- GILD $28,754,000,000.00
- DE $47,855,000,000.00
- Revenue This Year
- GILD $1.80
- DE N/A
- Revenue Next Year
- GILD $3.83
- DE $7.17
- P/E Ratio
- GILD $275.11
- DE $19.99
- Revenue Growth
- GILD 6.04
- DE N/A
- 52 Week Low
- GILD $62.07
- DE $340.20
- 52 Week High
- GILD $119.96
- DE $515.05
- Technical
- Relative Strength Index (RSI)
- GILD 43.51
- DE 46.72
- Support Level
- GILD $97.32
- DE $448.68
- Resistance Level
- GILD $107.18
- DE $472.78
- Average True Range (ATR)
- GILD 3.94
- DE 18.84
- MACD
- GILD -0.45
- DE 0.89
- Stochastic Oscillator
- GILD 41.42
- DE 63.42
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About DE Deere & Company
Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production & precision agriculture (PPA), small agriculture & turf (SAT), construction & forestry (CF), and financial services (FS), its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere financial provides retail financing for machinery to its customers and wholesale financing for dealers.